Temisis Therapeutics Competitors and Similar CompaniesClear all
Temisis Therapeutics's competitors and similar companies include S1 Biopharma, Vast Therapeutics, ReGen Therapeutics and Yamo Pharmaceuticals.
 Temisis Therapeutics Temisis Therapeutics is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing an inflammatory component. |  S1 Biopharma S1 Biopharma is a company developing drugs for the treatment of sexual dysfunction in both women and men. |  Vast Therapeutics Vast Therapeutics (formerly Novoclem Therapeutics) is a preclinical-stage pharmaceutical company developing a nitric oxide-based therapy to treat respiratory diseases. |  ReGen Therapeutics ReGen Therapeutics is a company that develops a proline-rich polypeptide complex derived from mammalian colostrum. |  Yamo Pharmaceuticals Yamo Pharmaceuticals is a company developing L1-79, a therapy that targets the core symptoms of autism. | |
Founding Date | Founding Date N/A | Founding Date 2008 | Founding Date 2017 | Founding Date 1998 | Founding Date N/A |
Type | Type Private | Type Private | Type Subsidiary | Type Private | Type Private |
Tags | |||||
Locations | Locations Vandœuvre-lès-Nancy, FR HQ | Locations New York, US HQ | Locations Durham, US HQ | Locations London, GB HQ London, GB | Locations HQ |
Employees | Employees 2 | Employees 4 | Employees 12 | Employees 3 | Employees 6 |
For sources of this data, please see the company profile
View Company Profiles
S1 Biopharma
HQ
New York, US
Employees
4
S1 Biopharma is a company developing drugs for the treatment of sexual dysfunction in both women and men.
View companyVast Therapeutics
HQ
Durham, US
Vast Therapeutics (formerly Novoclem Therapeutics) is a preclinical-stage pharmaceutical company developing a nitric oxide-based therapy to treat respiratory diseases.
View companyReGen Therapeutics
HQ
London, GB
Employees
3
ReGen Therapeutics is a company that develops a proline-rich polypeptide complex derived from mammalian colostrum.
View companyYamo Pharmaceuticals
HQ
Employees
6
Yamo Pharmaceuticals is a company developing L1-79, a therapy that targets the core symptoms of autism.
View company